Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Abasaglar

Lilly elects Prof Carolyn Bertozzi to board of directors

She brings oncology, inflammation and infection research expertise to the firm

- PMLiVE

FDA OKs Valeant’s psoriasis drug Siliq, with black box warning

Suicidal ideation labelling adds to challenge in rivalling Novartis’ Cosentyx and Lilly’s Taltz

- PMLiVE

Merck BACE inhibitor adds to litany of Alzheimer’s trial failures

Interim data shows “virtually no chance” of clinical success for verubecestat

Eli Lilly HQ

Lilly claims first place for JAK inhibitor Olumiant in EU

EMA approves once-daily rheumatoid arthritis drug ahead of Pfizer’s Xeljanz

- PMLiVE

Marathon pauses Emflaza launch amid pricing furore

US Senator Bernie Sanders calls Duchenne muscular dystrophy drug’s pricing “unconscionable”

Sanofi reception

Praluent can stay on market for now, says US court

Sanofi and Regeneron win appeal to suspended permanent injunction sought by Amgen

- PMLiVE

FDA approves first steroid for Duchenne muscular dystrophy

Marathon Pharma’s Emflaza is first approved to treat all genetic forms of the condition

- PMLiVE

Amgen’s chronic kidney disease drug Parsabiv cleared in US

Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years

- PMLiVE

Biotech leaders slam Trump over immigration order

Former Teva CEO Jeremy Levin heads open letter expressing “deep concern and opposition”

- PMLiVE

Cello Health expands with Defined Health acquisition

Builds US presence with biotech-focused strategy specialist

- PMLiVE

Sanofi appoints general manager UK

Hugo Fry previously served as chief marketing officer at Sanofi Pasteur

Roche Basel Switzerland

Tecentriq growth offsets Avastin’s US decline at Roche

Shifts focus to newer therapies in anticipation of brewing biosimilar competition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links